Ciraparantag TFA

CAS: 1438492-27-3 F: C26H50F6N12O6 W: 740.74

Ciraparantag TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoag

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Ciraparantag TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4].
Target	thrombin, factor Xa
Invitro	Ciraparantag TFA is a small-molecule antidote for unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and certain direct oral anticoagulants (DOACs)[2].Ciraparantag TFA is a small synthetic and cationic molecule that binds direct Xa inhibitors, direct thrombin inhibitors, and unfractionated and low molecular weight heparin (LMWH) through non-covalent hydrogen bonds and charge–charge interactions[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Ciraparantag TFA 相关抗体:
CAS	1438492-27-3
Formula	C26H50F6N12O6
Molar Mass	740.74
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25. [2]. Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10. [3]. Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44. [4]. Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158.

Methscopolamine bromide